Sana Biotechnology, Inc.
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
SANA$2.47+4.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except per share amounts)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Operating expenses: | |||
| Research and development | $131,980 | $215,673 | $261,809 |
| Research and development related success payments and contingent consideration | 29,432 | (8,881) | (48,981) |
| General and administrative | 44,296 | 64,040 | 73,299 |
| Impairment of long-lived assets | 44,611 | 1,891 | 7,014 |
| Total operating expenses | 250,319 | 272,723 | 293,141 |
| Loss from operations | (250,319) | (272,723) | (293,141) |
| Interest income, net | 3,848 | 10,471 | 9,938 |
| Other income (expense), net | 2,305 | (4,507) | (52) |
| Net loss | $(244,166) | $(266,759) | $(283,255) |
| Net loss per common share – basic and diluted | $(0.96) | $(1.16) | $(1.46) |
| Weighted-average number of common shares – basic and diluted | 253,234 | 230,891 | 194,541 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.